Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

A number of equities research analysts have weighed in on the company. Chardan Capital started coverage on Cognition Therapeutics in a report on Thursday, June 6th. They issued a “buy” rating and a $11.00 target price on the stock. HC Wainwright decreased their target price on Cognition Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Rodman & Renshaw reissued a “buy” rating and issued a $14.00 target price on shares of Cognition Therapeutics in a report on Tuesday, July 2nd. B. Riley restated a “neutral” rating and issued a $1.00 price target (down from $5.00) on shares of Cognition Therapeutics in a research note on Tuesday, August 6th. Finally, Cantor Fitzgerald downgraded shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 30th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CGTX. AWM Investment Company Inc. bought a new stake in Cognition Therapeutics during the 1st quarter worth approximately $1,183,000. Hohimer Wealth Management LLC bought a new stake in shares of Cognition Therapeutics in the first quarter worth $410,000. CM Management LLC increased its holdings in Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the period. Mercer Global Advisors Inc. ADV raised its position in Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the last quarter. Finally, Twin Focus Capital Partners LLC acquired a new position in Cognition Therapeutics during the 4th quarter worth about $173,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Stock Down 4.9 %

CGTX stock opened at $0.58 on Friday. Cognition Therapeutics has a 52 week low of $0.54 and a 52 week high of $2.95. The business has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.61. The company has a market cap of $23.22 million, a PE ratio of -0.63 and a beta of 1.41.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. During the same quarter in the prior year, the company posted ($0.16) EPS. On average, analysts anticipate that Cognition Therapeutics will post -0.87 EPS for the current fiscal year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.